Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

Resistance to imatinib has been recurrently reported in systemic mastocytosis (SM) carrying exon 17 KIT mutations. We evaluated the efficacy and safety of imatinib therapy in 10 adult SM patients lacking exon 17 KIT mutations, 9 of which fulfilled criteria for well-differentiated SM (WDSM). The Worl...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Alvarez-Twose, Iván, Matito, Almudena, Morgado, José Mário, Sánchez-Muñoz, Laura, Jara-Acevedo, María, García-Montero, Andrés, Mayado, Andrea, Caldas, Carolina, Teodósio, Cristina, Muñoz-González, Javier Ignacio, Mollejo, Manuela, Escribano, Luis, Orfao, Alberto
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Clinical Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620310/
https://ncbi.nlm.nih.gov/pubmed/28978170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10711
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items